Arcadia Biosciences Notified of Nasdaq Minimum Bid Deficiency

What Happened

• Arcadia Biosciences, Inc. (RKDA) announced it received a Nasdaq notice on August 4, 2026 that it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the company’s closing bid price was below the $1.00 minimum for the 30 consecutive business days from June 22, 2026 to August 3, 2026. The notice does not affect current trading — RKDA will continue to trade on The Nasdaq Capital Market.

Key Details

• Notice received: August 4, 2026 (based on closing bids June 22–August 3, 2026).
• Cure window: Initial 180-calendar-day compliance period ending February 1, 2027.
• Regain requirement: Closing bid must be at least $1.00 for a minimum of 10 consecutive business days during the compliance period (Nasdaq may require a longer period).
• Next steps/options: If eligible, Arcadia could request a second 180-day period (by meeting other listing standards and notifying Nasdaq) and may consider a reverse stock split to cure the deficiency. The company will monitor the bid price and evaluate options. Filing signed by CEO Thomas J. Schaefer (Aug 7, 2026).

Why It Matters

• For investors, this is a material notice because failure to regain the $1.00 minimum bid could lead to delisting proceedings, reduced liquidity, and potential negative impacts on share value and marketability. The stock will remain listed and tradable while the company attempts to cure the deficiency, and the company may take corporate actions (such as a reverse split) that would affect share counts and per‑share metrics.